A New Innova+ve Approach to Integrate Pa+ent Preferences into the Sta+s+cal Design for Clinical Trials: A Collabora+ve Case Study

Similar documents
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON S RESEARCH. Funding Opportunities

MJFF S VISION FOR PARTNERING WITH PATIENTS. Sohini Chowdhury The Michael J. Fox Foundation

speakers! Jeffrey E. Shuren MD, JD Steven Immergut MPH Janet Woodcock MD Margaret Anderson Director, Center for Drug Evaluation and Research

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials

ANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE

Agenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK

SUPPORT FEDERAL FUNDING FOR PARKINSON S DISEASE RESEARCH AND DRUG DEVELOPMENT

ONLY AT NYSCF Stem Cells in the City Sponsorship Offering

The summit and its purpose

USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research

A Blueprint for Breast Cancer Deadline 2020

Restoration. JDRF is turning Type One into Type None. attack so the newly restored beta cell function is protected.

Parkinson s Research Program

INTRODUCTION TO FOX TRIAL FINDER. Accelerating Clinical Trial Recruitment Online

Championing patients every step of the way

STRATEGIC PLAN

Innovation from the Foundation Sonya Dumanis, PhD

RESEARCH BUSINESS DEVELOPMENT MANAGER OVARIAN CANCER AUSTRALIA

Strategic Plan Executive Summary Society for Research on Nicotine and Tobacco

The Michael J. Fox Foundation & Gecko Ventures: The Parkinson s Disease Data Challenge

Leading the Way to Ending NF

1. The World Bank-GAVI Partnership and the Purpose of the Review

Research For the Future. Len Lichtenfeld, MD, MACP Interim Chief Medical and Scientific Officer

CONNECTING ABUNDANCE WITH NEED 2018 REPORT TO THE COMMUNITY

STRATEGIC PLAN

Type 1 Research Today

Treatments of tomorrow: dementia research and drug discovery. Dr Matthew Norton Director of Policy and Strategy, Alzheimer s Research UK

Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards

Bobby Goldsmith Foundation Strategic Plan

REPORT CROHN S AND COLITIS CANADA. Make it stop. For life.

Fast-Forwarding a Cure for Melanoma

empower youth mentor

To find a cure for Parkinson s

SPONSORSHIP OPPORTUNITIES

Mental Health, Substance Abuse & Primary Care: Bridging Gaps in Access

Population Council Strategic Priorities Framework

INSPIRING COMMUNITY ACTION ON CLIMATE The film to get YOU talking about climate!

9 th Annual Westchester-Fairfield VisionWalk!

VALUE TO A SPONSOR PARTNER OR DONOR. Dementia Alliance International

CDNF: Finnish academia-industry collaboration for unique clinical study in Parkinson s disease

ABOUT THIS DOCUMENT WHAT WE DO

Strategic Fundraising: Institutional Giving Strategies, Models & Priorities October 24, 2018

PARTNERS FOR A HUNGER-FREE OREGON STRATEGIC PLAN Learn. Connect. Advocate. Partners for a Hunger-Free Oregon. Ending hunger before it begins.

Strategic Plan

FY12 FY14 Strategic Plan

Tuberous Sclerosis Australia Strategic Plan

Biomedical Research Strategy Making sure there are effective treatments for deafness, hearing loss and tinnitus

Strategic Plan

APDA Tulsa Optimism Walk 2018 Sponsorship Proposal

Aiming High Our priorities by 2020 HALFWAY THERE. Our priorities by 2020

I. CHESTER COUNTY COMMUNITY FOUNDATION GRANT PROPOSAL SUMMARY SHEET Date September 20, 2018

FP2020 MIDPOINT COMMUNICATIONS TOOLKIT. #FP2020Progress

To benefit Parent Project Muscular Dystrophy In honor of Elliott and Henry Johnson

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC

Chief Development Officer National Brain Tumor Society

2018 WALK TO END HYDROCEPHALUS Twin Cities, MN SPONSORSHIP OPPORTUNITIES

YEARS & COUNTING Annual Report

Position Profile Chief Executive Officer Feeding America San Diego San Diego, CA

Common Data Elements: Making the Mass of NIH Measures More Useful

GuideStar Impact Call

APDA Oklahoma Optimism Walk 2017 Sponsorship Proposal

Job information pack Interim Head of Strategic Marketing

ALS ACT (Accelerated Therapeutics)

THE 3 RD ANNUAL TAKE A SEAT AUCTION FOR CHARITY

THE RARE DISEASES CLINICAL RESEARCH NETWORK AS A NESTED CULTURAL COMMONS

Gala Honorees Rebecca and Bill Power

4. Project Inform does receive restricted donations from corporations, non-profits, foundations, and government entities.

LEADERSHIP PROFILE. CURE Childhood Cancer believes that childhood cancer can be cured in our lifetime. -- CURE Childhood Cancer s Vision

Call for Strategic Partners, Sponsors and Exhibitors

Interested in Becoming a PTA?

SPONSORSHIP OPPORTUNITIES. The Gatsby Gala COCKTAILS AND CASINO TABLES TO BENEFIT THE TY LOUIS CAMPBELL FOUNDATION

Advancing Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation Day 2

CHILD ENDS HERE HOMELESSNESS. 3 Year Strategic Plan Inn from the Cold 3 Year Strategic Plan

about our mission to End Women's Cancer foundationforwomenscancer.org

Melanoma. Research Alliance. Fast-Forwarding a Cure for Deadly Skin Cancer

PARTNER WITH JDRF AS A SPONSOR OF THE 35TH ANNUAL JDRF BOSTON GALA. Saturday, May 13, o clock Boston Marriott Copley Place Grand Ballroom

Paint the Night Purple

PROFESSIONAL BUSINESS FRATERNITY CORPORATE SPONSORSHIP PROPOSAL

Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016

Gavi s private sector engagement approach

Gala Honorees Rebecca and Bill Power

Driving access to medicine

Association of American Cancer Institutes

Who we are. We envision a world where high quality eye health and vision care is accessible to all people.

The Global AIESEC Leadership Initiative. Leadership for a Better World

Eradicating cervical cancer. Our role in making it a reality

The Training & Education Unit of F-CRIN's head office. Project manager

MRCG Strategic Document

Start a Team. Join a Team. Make a Difference! ALZ.ORG/WALK

ANNUAL REPORT 2014 FINDING CONNECTIONS FINDING A CURE

MobileCause Academy Training #GI INGTUESDAY & YEAR-END GIVING STRATEGIES AND CAMPAIGN PLANNING

E-Newsletter Samples For The Cutaneous Lymphoma Foundation

Media Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) (908)

Call for Strategic Partners, Sponsors and Exhibitors

The Global AIESEC Leadership Initiative. Leadership for a Better World

STRATEGIC PLAN 2014 to 2017

FIGHT ON THE BEACHES

Expanding the boundaries of nutrition Luis Cantarell

Who we are. We envision a world where high quality eye health and vision care is accessible to all people.

Transcription:

A New Innova+ve Approach to Integrate Pa+ent Preferences into the Sta+s+cal Design for Clinical Trials: A Collabora+ve Case Study A Collabora)on of the Medical Device Innova)on Consor)um, FDA, MIT, RTI Health Solu)ons and the Michael J. Fox Founda)on for Parkinson s Research #Patients2018

Our Speakers Heather Benz, FDA Center for Devices and Radiological Health Margaret Sheehan, The Michael J. Fox Foundation for Parkinson s Research Lauren McLaughlin, The Michael J. Fox Foundation for Parkinson s Research Stephanie Christopher, Medical Device Innovation Consortium Annie Saha, FDA Center for Devices and Radiological Health #Patients2018

Heather Benz, FDA Center for Devices and Radiological Health #Patients2018

Pa)ents are at the Heart of What We Do CDRH Vision: Patients in the U.S. have access to high-quality, safe, and effective medical devices of public health importance first in the world 4

What if pa)ents urgency for new therapeu+c op+ons and tolerance of uncertainty were taken into account when designing and sizing clinical trials? 5

Specific Aims www.fda.gov 6

Iden+fying Outcomes 1 Ac+vity Par+cipants www.fda.gov Iden)fy and develop preliminary list of poten)al amributes through literature review Iden)fy Refine Priori)ze Define Sponsors Pa)ents Physicians Sponsors Pa)ents Physicians Pa)ents Physicians Sponsors 7

Iden+fying Outcomes Refine and clarify amributes through 2 discussion and focus groups Ac+vity Par+cipants www.fda.gov Iden)fy Refine Sponsors Pa)ents Physicians Sponsors 8

Iden+fying Outcomes Priori)ze amributes by using ranking surveys 3 groups and discussion Ac+vity Par+cipants www.fda.gov Iden)fy Refine Priori)ze Sponsors Pa)ents Physicians Sponsors Pa)ents Physicians 9

Iden+fying Outcomes Develop unbiased, pa)ent-centered descrip)ons in discussion groups 4 Ac+vity Par+cipants www.fda.gov Iden)fy Refine Priori)ze Define Sponsors Pa)ents Physicians Sponsors Pa)ents Physicians Pa)ents Physicians Sponsors 10

Margaret Sheehan, The Michael J. Fox Foundation for Parkinson s Research #Patients2018

Lauren McLaughlin, The Michael J. Fox Foundation for Parkinson s Research #Patients2018

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON S RESEARCH

MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson s disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson s today. Vital Stats» Founded in 2000 by actor Michael J. Fox» Public charity» More than 85,000 donors in 2016 (individuals, corporations, nonprofits)» No chapters: team of 125 based in NYC» 4,200 grassroots fundraisers reaching 175,000 supporters worldwide in 2016» Over 30,000 emails were sent to members of Congress on critical Parkinson s issues in 2016» Nearly $750 million in research programs funded to date» $90 million in research programs funded in 2016» More than 2,600 projects funded to date» More than 600 active grants in current portfolio» 34% of funded projects are led by researchers outside the United States» Fund academics, biotechs and pharma 14

PATIENTS NEEDS DRIVE OUR EFFORTS MJFF was founded by a person with Parkinson s disease. Assessing all potential projects through a patientfocused lens, everything we do is driven by the many unmet medical needs of Parkinson s patients today. 15

WE TAKE A HOLISTIC APPROACH TO OUR WORK We drive promising therapeutic targets while also investing to make PD drug development faster, cheaper, and more attractive. Our work is not done. Therefore, we seek collaboration to accelerate ongoing activities and launch initiatives in parallel. 16

Stephanie Christopher, Medical Device Innovation Consortium #Patients2018

A novel method (and a novel team) for incorporation of patient preferences in clinical trial design

Why MDIC? MDIC is a 501(c)(3) non-profit organization and is the first-ever public-private partnership created with the sole objective of advancing regulatory science of medical devices for patient benefit

What is Regulatory Science? FDA Strategic Plan, August 2011 Advancing Regulatory Science at FDA The science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products Benefits patients by speeding the rate of important technologies reaching market Reduces time and resources needed for device development, assessment, and review. For example: Ø Can lead to quicker, more efficient device approvals Ø Can decrease the size and duration of premarket clinical trials Faster, Safer, More Cost-effective www.mdic.org

Why this matters to MDIC members Meeting patient needs CDRH commitment to advancing use of patient preference Potential for smaller clinical trials http://www.milkenreview.org/articles/p-values-vs-patient-values

Annie Saha, FDA Center for Devices and Radiological Health #Patients2018

Looking Forward CDRH is commimed to integra)ng the pa)ent voice into our regulatory decision-making CDRH encourages pa)ent groups, industry, and others to interact with us early to discuss how pa)ent input can be used for regulatory purposes Partnerships are key to advancing the science of pa)ent input Other ways to incorporate pa)ent input Improve communica)on of benefit-risk informa)on to pa)ents Incorporate pa)ent input to inform clinical trial design Encourage PRO development and use 23

Pa)ents are at the Heart of What We Do CDRH Vision: Patients in the U.S. have access to high-quality, safe, and effective medical devices of public health importance first in the world 24

Tool Box Notes For our toolbox contribu)on, we would like to share a handout we created on the first steps for sponsors to consider when thinking about launching a pa)ent preference study. You can download the tool at: hmp://mdic.org/wp-content/uploads/2016/04/ Pa)ent-Preference-Study-Design-20171102.pdf #Patients2018

Our Speakers Heather Benz, FDA Center for Devices and Radiological Health Margaret Sheehan, The Michael J. Fox Foundation for Parkinson s Research Lauren McLaughlin, The Michael J. Fox Foundation for Parkinson s Research Stephanie Christopher, Medical Device Innovation Consortium Annie Saha, FDA Center for Devices and Radiological Health #Patients2018

Join us May 18 to hear the final results of the project hmp://mdic.org/spi/pcor/workshop #Patients2018